Spots Global Cancer Trial Database for advanced cancer
Every month we try and update this database with for advanced cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer | NCT00664170 | Advanced Cancer | ANX-514 docetaxel | 18 Years - | Mast Therapeutics, Inc. | |
| A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH) | NCT06210776 | HER2-positive B... HER2-low Breast... Breast Cancer Advanced Cancer | Trastuzumab der... | 18 Years - | Daiichi Sankyo | |
| Meaning-Centered Pain Coping Skills Training | NCT04431830 | Advanced Solid ... Pain | Meaning-Centere... | 18 Years - | Duke University | |
| Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | NCT02807844 | Triple Negative... Pancreatic Carc... Melanoma Endometrial Car... | MCS110 PDR001 | 18 Years - | Novartis | |
| A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma | NCT03470922 | Melanoma | Relatlimab Nivolumab | 12 Years - | Bristol-Myers Squibb | |
| Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors | NCT03510104 | Advanced Cancer Metastatic Canc... Neoplasms Neoplasm Metast... Neoplastic Proc... Pathologic Proc... | MRX-2843 | 18 Years - | Meryx, Inc. | |
| Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer | NCT01538563 | Solid Tumors Advanced Cancer Cancer Neoplasms | rigosertib sodi... | 18 Years - | Traws Pharma, Inc. | |
| Safety Study of Whole Body Hyperthermia for Advanced Cancer | NCT04467593 | Advanced Cancer Pancreatic Canc... | Whole body hype... Standard of Car... | 18 Years - 75 Years | ElmediX | |
| CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma | NCT05257590 | Hepatocellular ... Advanced Cancer | Nivolumab Injec... CVM-1118 | 18 Years - | TaiRx, Inc. | |
| Cross Sectional Study of Constipation in Advanced Cancer Patients | NCT01399294 | Palliative Care Constipation Traditional Chi... | 18 Years - | Yan Chai Hospital | ||
| Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients | NCT00877773 | Advanced Cancer... | Temsirolimus | - | M.D. Anderson Cancer Center | |
| Collaborative Care Intervention for Cancer Caregivers | NCT02944136 | Depression Advanced Cancer | enhanced usual ... stepped collabo... | 21 Years - | University of Pittsburgh | |
| A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies | NCT06120075 | Advanced Cancer | AB801 Zimberelimab Docetaxel | 18 Years - | Arcus Biosciences, Inc. | |
| Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers | NCT00798252 | Advanced Cancer | Capecitabine Doxorubicin Ixabepilone Docetaxel Paclitaxel Brivanib alanin... | 18 Years - 75 Years | Bristol-Myers Squibb | |
| A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer | NCT00664170 | Advanced Cancer | ANX-514 docetaxel | 18 Years - | Mast Therapeutics, Inc. | |
| Study of Amblyomin-X in Advanced Solid Tumor | NCT03120130 | Advanced Cancer | Amblyomin-X | 18 Years - 75 Years | União Química Farmacêutica Nacional S/A | |
| Osteopathy Treatment for Cancer Pain Related to the Confinement to Bed | NCT03440957 | Cancer Patient ... | Osteopathic tre... | 18 Years - | Hospices Civils de Lyon | |
| Clinical Study on the Treatment of Advanced Recurrent Tumors With Anticancer Mouse Characteristic Human Neutrophils | NCT06240767 | Solid Tumor, Ad... Advanced Cancer | Granulocyte inf... | 18 Years - 75 Years | Wuxi People's Hospital | |
| A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | NCT06440005 | Cancer Advanced Cancer Locally Advance... Metastatic Soli... Triple Negative... Pancreas Cancer Pancreatic Aden... | AGX101 | 18 Years - | Angiex, Inc. | |
| Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers | NCT03568058 | Advanced Cancer | personalized va... Pembrolizumab | 18 Years - | University of California, San Diego | |
| Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients | NCT00877773 | Advanced Cancer... | Temsirolimus | - | M.D. Anderson Cancer Center | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Impact of a Resource-based Life Review Intervention on Advanced Cancer Patients | NCT04254926 | Advanced Cancer | Revie ⊕ | 18 Years - | School of Health Sciences Geneva | |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas | NCT00553189 | Solid Tumors Lymphomas | ABT-888 Topotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML | NCT03690154 | Advanced Cancer Solid Tumors Acute Myeloid L... Acute Myeloid L... | FN-1501 | 18 Years - | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | |
| Psilocybin Therapy in Advanced Cancer | NCT05398484 | Advanced Cancer | Psilocybin 25 m... Niacin 100mg Psychotherapy | 21 Years - 100 Years | NYU Langone Health | |
| A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors | NCT04991480 | Advanced Cancer Metastatic Canc... Breast Cancer | ART4215 Talazoparib Niraparib | 18 Years - | Artios Pharma Ltd | |
| STAT3 Inhibitor for Solid Tumors | NCT00955812 | Advanced Cancer Solid Tumor | OPB-31121 | 18 Years - | M.D. Anderson Cancer Center | |
| Randomized Controlled Trial of Integrated Early Palliative Care | NCT03181854 | Advanced Cancer Solid Tumor | Telephone coach... Consultation wi... | 20 Years - | Seoul National University Hospital | |
| A Feasibility Study of a Virtual Rehabilitation and Physical Activity Program for People With Advanced Cancer | NCT05047042 | Advanced Cancer | Advanced Cancer... | 18 Years - | University of Alberta | |
| Study of Noni in Cancer Patients | NCT00033878 | Neoplasms Neoplasm Metast... | Noni Extract | - | National Center for Complementary and Integrative Health (NCCIH) | |
| Safety Study of FLP Injection to Treat Tumor Patients | NCT01361529 | Advanced Cancer | FLP,dose escala... | 18 Years - 70 Years | Acea Bio (Hangzhou) Co., Ltd. | |
| AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors | NCT03579628 | Advanced Cancer | AsiDNA | 18 Years - | Valerio Therapeutics | |
| Perception Prognosis, Goals of Treatment, and Communication | NCT01401894 | Gastric Cancer Esophageal Canc... Pancreatic Canc... Liver Cancer Biliary Cancer | 18 Years - | Massachusetts General Hospital | ||
| Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer | NCT02219711 | Advanced Cancer | MGCD516 | 18 Years - | Mirati Therapeutics Inc. | |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | NCT04660929 | HER2-positive Adenocarcinoma Bile Duct Cance... Biliary Tract C... Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Duct... Carcinoma, Hepa... Cancer Lung Cancer, No... Carcinoma, Ovar... Carcinoma, Smal... Carcinoma, Squa... Carcinoma, Tran... Colorectal Canc... Esophagogastric... Inflammatory Br... Stomach Neoplas... Malignant Neopl... Ovarian Neoplas... Pancreatic Canc... HER2-positive S... HER2-positive B... HER2-positive G... HER-2 Protein O... HER-2 Gene Ampl... Prostate Cancer Head and Neck C... Endometrial Can... Lung Cancer, Sm... | CT-0508 Pembrolizumab | 18 Years - | Carisma Therapeutics Inc | |
| Acceptance and Commitment Therapy in Patients With Advanced Lung Cancer | NCT04869267 | Lung Cancer Advanced Cancer | Acceptance and ... Usual care | 18 Years - | Chinese University of Hong Kong | |
| Mirtazapine for Treatment of Cancer Associated Anorexia-cachexia | NCT03254173 | Advanced Cancer Cancer Associat... | Mirtazapine 30 ... Placebo oral ta... | 18 Years - | Kasr El Aini Hospital | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Effects of Receptive Music Therapy Combined With Virtual Reality on Prevalent Symptoms in Patients With Advanced Cancer | NCT05603767 | Music Therapy | RMT+ VR | 18 Years - | Austral University, Argentina | |
| Care Transition Intervention for Hospitalized Patients With Advanced Cancer | NCT05142345 | Cancer Follow-Up Care Consultation, R... Advanced Cancer | CONTINUUM Inter... Usual Care | 18 Years - | Massachusetts General Hospital | |
| A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer | NCT03507166 | Urothelial Carc... Advanced Cancer | RC48-ADC | 18 Years - 80 Years | RemeGen Co., Ltd. | |
| A First-in-human (FIH), Multicenter, Open-Label, Phase I Study of PTX-912 in Patients With Locally Advanced/Metastatic Solid Tumors | NCT06190886 | Advanced Cancer Solid Tumor Metastatic Canc... | PTX-912 | 18 Years - | Proviva Therapeutics, Inc. | |
| Study of AZD8931 in Patients With Advanced Solid Malignancies | NCT00637039 | Advanced Solid ... | AZD8931 | 18 Years - | AstraZeneca | |
| Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN) | NCT04606940 | Head and Neck C... Advanced Cancer Metastatic Canc... HNSCC Squamous Cell C... | 18 Years - | University Health Network, Toronto | ||
| A Prospective Dose Finding Study of Iscador Infusion | NCT04376931 | Advanced Cancer | Intravenous Sol... | 18 Years - | HaEmek Medical Center, Israel | |
| Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors | NCT04678921 | Solid Tumor Metastatic Canc... Advanced Cancer | TJ210001 | 18 Years - 99 Years | I-Mab Biopharma US Limited | |
| Communication Strategies to Introduce Psychology Services | NCT03035448 | Malignant Neopl... | Questionnaires Video Presentat... | 18 Years - | M.D. Anderson Cancer Center | |
| PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies | NCT03030001 | Solid Tumor, Ad... Advanced Cancer | PD-1 antibody e... | 18 Years - 80 Years | Ningbo Cancer Hospital | |
| Engagement of Patients With Advanced Cancer | NCT02966509 | End of Life Advanced Cancer Lung Neoplasm Gastric Cancer Colon Cancer Glioblastoma Mu... Head and Neck N... Rectum Cancer Melanoma Kidney Cancer Prostate Cancer Testicular Neop... Liver Cancer Cancer of Unkno... | EPAC | 18 Years - | Stanford University | |
| Risk Stratification for Patients With Hospital-diagnosed Advanced Lung Cancer | NCT05722847 | Lung Cancer | 18 Years - | UNC Lineberger Comprehensive Cancer Center | ||
| Decision Aid to Support Advanced Cancer Patients | NCT04606238 | Advanced Cancer | Decision Aid | 18 Years - | University Hospital Heidelberg | |
| UC Health Care Planning Study | NCT04012749 | Advance Care Pl... Advance Directi... Advanced Cancer | Advance directi... Prepare Facilitator | 18 Years - | University of California, Los Angeles | |
| Study of Erlotinib in Combination With Bortezomib | NCT00895687 | Advanced Cancer | Erlotinib Hydro... Bortezomib | - | M.D. Anderson Cancer Center | |
| A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer | NCT02507544 | Carcinoma Advanced Cancer | TRX-818 capsule... | 18 Years - | TaiRx, Inc. | |
| A Study of Anti-Lewis Y Chimeric Antigen Receptor-T Cells (LeY-CAR-T) in Patients With Solid Tumours | NCT03851146 | Advanced Cancer | LeY CAR T cells | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer | NCT01423903 | Advanced Cancer | OPB-51602 | 18 Years - | Otsuka Pharmaceutical Development & Commercialization, Inc. | |
| A Study of ARRY-142886 in Patients With Advanced Cancer | NCT00085787 | Advanced Cancer | ARRY-142886, ME... | 18 Years - | Array BioPharma | |
| A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas | NCT01051635 | Neoplasms Lymphoma | LMP400 LMP776 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study in Advanced Cancer | NCT01226485 | Advanced Cancer | Taladegib | 18 Years - | Eli Lilly and Company | |
| Study of Temsirolimus, Topotecan, and Bortezomib | NCT00770731 | Advanced Cancer | Torisel (Temsir... Hycamtin (Topot... Velcade (Bortez... | - | M.D. Anderson Cancer Center | |
| Assessing the Immunogenicity of pING-hHER3FL | NCT03832855 | Advanced Cancer | pING-hHER3FL | 18 Years - | Duke University | |
| Plasmodium Immunotherapy for Advanced Cancers | NCT03375983 | Advanced Cancer... | Blood-stage inf... | 18 Years - 70 Years | CAS Lamvac Biotech Co., Ltd. | |
| Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer | NCT03029403 | Advanced Cancer Ovarian Cancer Primary Periton... Fallopian Tube ... | Pembrolizumab DPX-Survivac Cyclophosphamid... | 18 Years - | University Health Network, Toronto | |
| A Dose-escalation Study in Subjects With Advanced Malignancies | NCT01072266 | Solid Tumor Advanced Cancer Metastatic Canc... | INCB028060 | 18 Years - | Incyte Corporation | |
| A Study Explore JS001+JS002 in Patients With Advanced Cancer | NCT05128539 | Advanced Cancer | JS001(Toripalim... | 18 Years - 75 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| Living With Hope Program for Rural Women Caregivers | NCT01081301 | Advanced Cancer | Living with Hop... | 18 Years - | University of Saskatchewan | |
| Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer | NCT00101907 | Lung Cancer Pancreatic Canc... Esophageal Canc... | AMG 706 Panitumumab Gemcitabine Cisplatin | 18 Years - | Amgen | |
| Doxil, Bevacizumab and Temsirolimus Trial | NCT00761644 | Advanced Cancer | Doxil Bevacizumab Temsirolimus | 12 Years - | M.D. Anderson Cancer Center | |
| Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies | NCT01463982 | Solid Tumor Advanced Cancer | Oratecan and Ca... | 19 Years - | Hanmi Pharmaceutical Company Limited | |
| Doxil, Bevacizumab and Temsirolimus Trial | NCT00761644 | Advanced Cancer | Doxil Bevacizumab Temsirolimus | 12 Years - | M.D. Anderson Cancer Center | |
| Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer | NCT01596140 | Advanced Cancer Solid Tumor | Vemurafenib Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| LY3214996 +/- HCQ in Pancreatic Cancer | NCT04386057 | Pancreatic Canc... Advanced Cancer | Hydroxychloroqu... LY3214996 | 18 Years - | Dana-Farber Cancer Institute | |
| A Dose-Escalation Study for Patients With Advanced Cancer | NCT01214642 | Advanced Cancer | pegfilgrastim LY2523355 | 18 Years - | Eli Lilly and Company | |
| Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers | NCT04270864 | Advanced Cancer | Ipilimumab Nivolumab Tilsotolimod | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| DM-CHOC-PEN Plus Radiation for Brain Tumors | NCT03371004 | Advanced Cancer | 4-Demethyl-4-ch... | 21 Years - | DEKK-TEC, Inc. | |
| FdCyd and THU for Advanced Solid Tumors | NCT01534598 | Neoplasms | FdCyd + THU | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Transcutaneous Electrical Nerve Stimulation (TENS) for Advanced Cancer Pain Patients | NCT02655289 | Advanced Cancer | Modulated TENS Placebo TENS | 18 Years - | University Hospital Freiburg | |
| An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment | NCT03335540 | Advanced Cancer | Nivolumab Relatlimab Cabiralizumab Ipilimumab IDO1 Inhibitor Radiation Thera... | 18 Years - | Bristol-Myers Squibb | |
| Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients | NCT05375994 | Non Small Cell ... KRAS Activating... Advanced Cancer Metastatic Canc... Malignant Neopl... Malignant Neopl... | avutometinib (V... | 18 Years - | Verastem, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
